Recruiting PHASE2 INTERVENTIONAL 2-arm NCT06639282

Repurposing Siponimod for Alzheimer's Disease (SIPO1-AD)

SIPO1-AD: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Siponimod in Patients With Mild Alzheimer's Disease

Sponsor: Arizona State University

Conditions Alzheimer Disease Cognitive Impairment, Mild MCI With Increased Risk for Alzheimer Disease Mild Alzheimer Disease

Interventions Placebo Siponimod

Updated 3 times since 2024 Last updated: Mar 2, 2026 Started: Aug 26, 2025 Primary completion: Oct 31, 2029 Completion: Oct 31, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Alzheimer Disease and Cognitive Impairment, Mild and is currently actively recruiting participants. Arizona State University leads this study, which shows 3 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

3 versions recorded

Mar 2026 — Present [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jun 2025 — Mar 2026 [monthly]

Not Yet Recruiting PHASE2
Nov 2024 — Jun 2025 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Arizona State University
Laboratory Corporation of America
National Institute on Aging (NIA)
Novartis
St. Joseph's Hospital and Medical Center, Phoenix
Texas Tech University Health Sciences Center

Data source: St. Joseph's Hospital and Medical Center, Phoenix

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Phoenix, United States